11/26
01:19 pm
radx
Radiopharm Theranostics (NASDAQ:RADX) had its price target lowered by analysts at B. Riley from $15.00 to $13.00. They now have a "buy" rating on the stock.
Low
Report
Radiopharm Theranostics (NASDAQ:RADX) had its price target lowered by analysts at B. Riley from $15.00 to $13.00. They now have a "buy" rating on the stock.
11/18
08:30 am
radx
Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer
Medium
Report
Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer
11/17
08:00 am
radx
Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases
Low
Report
Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases
11/12
08:30 am
radx
Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204
Medium
Report
Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204
10/20
08:00 am
radx
Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs
Medium
Report
Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs
10/20
07:30 am
radx
Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan
Medium
Report
Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan
10/1
08:00 am
radx
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 ‘HEAT’ Dose Escalation Clinical Trial
Medium
Report
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 ‘HEAT’ Dose Escalation Clinical Trial